Clinical Trials
14 trialsNCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03805594 2025-02-25
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Completed
NCT03248570 2024-11-20
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Phase 2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02635672 2024-11-15
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1 Completed
NCT02325557 2024-04-02
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis, Inc.
Phase 1/2 Completed
NCT02499835 2023-08-01
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 1/2 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT02489357 2021-11-12
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed